Analytical method development and validation for pre-clinical analysis

Journal of Pharmaceutical Sciences and Research

Volumn 2, Issue 12, 2010, Pages 795-803

  Chandramouli, R ^a   Pavan Kumar, Pondugula ^a   Bibhishan, Kale Vishal ^a  

^a SASTRA UNIVERSITY   (India)

Author keywords

Analysis; Method development; Pre clinical phase

Indexed keywords

ANALYTIC METHOD; ANALYTICAL EQUIPMENT; ARTICLE; AUTOMATION; DILUTION; DRUG CONTROL; DRUG DETERMINATION; DRUG FORMULATION; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG STABILITY; FOOD AND DRUG ADMINISTRATION; GOOD LABORATORY PRACTICE; LABORATORY TEST; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; PROCESS DESIGN; QUALITY CONTROL; REPRODUCIBILITY; SAMPLING; SENSITIVITY AND SPECIFICITY; SEPARATION TECHNIQUE; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

EID: 79251507296     PISSN: None     EISSN: 09751459     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Lee MS, Kerns ED. LC/MS applications in drug development. Mass Spectrum. Rev 1999; 18: 187-279
2. Gu H, Unger S, Deng Y. Automated Tecan programming for bioanalytical sample preparation With EZTecan. Assay Drug Dev Technol 2006; 4: 721-733
3. Kyranos JN, Cai H, Wei D, Goetzinger WK. High-throughput high-performance liquid chromatography/mass spectrometry for modern drug discovery. Curr Opin Biotechnology 2001; 12: 105-111
4. Brewer E, Henion J. Atmospheric pressure ionization LC/MS/MS techniques for drug Disposition studies. J Pharm Sci 1998; 87: 395-402
5. Jemal M, Xia Y.-Q. LC-MS development strategies for quantitative bioanalysis. Curr Drug Metab 2006; 7: 491-502
6. Hsieh Y, Wang G, Wang Y, Chackalamannil S, Brisson, J-M, Ng K, Korfmacher WA. Simultaneous determination of a drug candidate and its metabolite in rat plasma samples using ultrafast monolithic column high-performance liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrum 2002; 16: 944-950
7. Taylor PJ. Matrix effects: the Achilles heel of quantitative high-performance liquid chromatography-electro spray-tandem mass spectrometry-Analytical Method Validation. Clin Biochem 2005; 38 (4):328-334.
8. Garfield FM, Klesta E, Hirsch J, Eds. Quality Assurance Principles for Analytical Laboratories, 3rd ed. Gaithersburg: AOAC International; 2000
9. Shah VP, Midha KK, Dighe SV, McGiveray JJ, S Kelly JO, Yacobi A, Laylogg T Viswanathan CT, Cook CE McDowall RD, Putman KA, Spector S. Analytical method Validation Assessment: bioavailability, bioequivalence, and PK studies. J Pharm Sci 1992; 81: 309-312
10. Kuklenyik Z, Ye X, Reich JA, Needham LL, Calafat AM. Automated online and off-line sample preparation & solid-phase extraction methods for measuring isofl avones and lignans in urine.J Chromatogr Sci 2004; 42 (9): 495-500
11. Li F, Zhang C, Guo X, Feng W. Sample preparation & Chemiluminescence detection in HPLC and CE for pharmaceutical and biomedical analysis. Biomed Chromatogr 2002; 17 (2-3): 96-105.
12. Vas G, Vekey K. Solid-phase microextraction: a powerful sample preparation tool prior to mass spectrometric analysis. J Mass Spectrum 2004; 39 (3): 233-254
13. Ohkura Y, Kai M, Nohta H. Fluorogenic reactions for biomedical chromatography. J Chromatogr B Biomed Appl 1994; 659 (1-2): 85-107
14. Halket JM, Zaikin VV. Derivatization in mass spectrometry-3. Alkylation (arylation). Eur J Mass Spectrum (Chichester) 2004; 10 (1): 1-19.
15. Lyubimov AV, Garry VF, Carlson RE, Barr DB, Baker SE. Simplified urinary immunoassay for 2, 4-D: validation and exposure assessment. J Lab Clin Med 2000; 136: 116-124
16. Grisanti V, Zachowski EJ. Operational and performance qualification. LCGC North America 2002; 20 (4): 356-362
17. Huber L. Validation and Qualification in Analytical Laboratories. Boca Raton, FL: CRC Press; 1999.
18. Chan CC, Herman Lam H, Lee YC, Xue-Ming Zhang XM, Eds. Analytical Method Validation and Instrument Performance Verification. Hoboken, NJ: Wiley; 2004.
19. Bansal SK, Layoff T, Bush ED, Hamilton M, Hankinson EA, Landy JS. Qualification of analytical instruments for use in the pharmaceutical industry: a scientific approach. AAPS PharmSciTech 2004; 5 (1): E22
20. Guidance for Industry: Analytical Procedures and Methods Validation, Chemistry, Manufacturing and Controls Documentation. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration; 2000. http://www.fda.gov/cder/ guidance/2396dft.pdf.
21. ICH Q1A (R2): Stability Testing of New Drug Substances and Products (Second Revision). Fed Reg 2003; 68(225):2844-2945 http://www.ich.org/MediaServer.jser?@_ID=419&@MODE=GLB
22. ICH Q1B: Photo stability Testing of New Drug Substances and Products. Fed Reg 1997; 62(95):27115-27122. http://www.ich.org/MediaServer.jser?@_ID=412&@MODE=GLB
23. ICHQ1C: StabilityTesting for New Dosage Forms. Fed Reg 1997;62(90):25634-25635. http://www.ich.org/MediaServer.jser?@_ID=413&@_MODE=GLB
24. ICH Q1D: Bracketing and Matrixing Designs for Stability Testing of Drug Substances and Drug Products. Fed Reg 2003; 68(11):2339-2340. http://www.ich.org/MediaServer.jser?@_ID=414&@_MODE=GLB.
25. ICH Q1E: Evaluation of Stability Data. Fed Reg2004; 69(110):32010-32011. http://www.ich.org/MediaServer.jser?@_ID=415&@_MODE=GLB
26. ICH Q1F: Stability Data Package for Registration Applications in Climatic Zones III and IV. Fed Reg 2003;68(225):65717-65718. http://www.ich.org/MediaServer.jser?@_ID=416&@_MODE=GLB
27. ICH Q3C: Impurities: Guideline for Residual Solvents. Fed Reg 1997;62(247):67377.http://www.ich.org/MediaServer.jser?@_ID=423&@_MODE=GLB
28. Q9: Quality Risk Management. Fed Reg 2005; 70(151):45722-45723. http://www.ich.org/LOB/media/MEDIA1957.pdf.
29. ISO9000:2000 Quality Management Systems-Fundamentals and Vocabulary. Geneva, Switzerland: International Organization for Standardization; 2000
30. ISO/IEC DIS 17025: General Requirements for the Competence of Testing and Calibration Laboratories. Geneva, Switzerland: International Organization for Standardization; 1998.
31. Taylor JK. Quality Assurance of Chemical Measurements. Chelsea, MI: Lewis Publishers; 1987, p 36
32. Reviewer Guidance: Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); 1994. http://www.fdagov/cder/guidance/cmc3.pdf.